MIR219A2: A Potential Drug Target and Biomarker (G407003)
MIR219A2: A Potential Drug Target and Biomarker
MIR219A2, a protein encoded by the immune response gene IRIS-2, is a highly conserved non-coding RNA molecule that plays a critical role in the regulation of immune responses and inflammation. MIR219A2 has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.
The MIR219A2 gene is located on chromosome 19q31 and has a length of approximately 219 amino acid residues. MIR219A2 is highly conserved across various species, with similar or identical sequences found in multiple organisms, including humans, mouse, and various bacteria. This conservation suggests that MIR219A2 may be a widely applicable protein and could be a useful biomarker for studying gene function in different organisms.
Several studies have identified MIR219A2 as a potential drug target in various diseases. For example, MIR219A2 has been shown to be highly expressed in various cancer types, including breast, ovarian, and colorectal cancer. Additionally, MIR219A2 has been shown to play a role in the regulation of immune responses and has been implicated in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.
One of the key features of MIR219A2 is its ability to interact with various signaling pathways and proteins. For example, MIR219A2 has been shown to interact with the protein NF-kappa-B, which is a transcription factor that plays a role in inflammation and immune responses. This interaction suggests that MIR219A2 may be involved in the regulation of immune responses and inflammation, which could make it a potential drug target for diseases that are characterized by chronic inflammation or immune dysregulation.
Another potential mechanism by which MIR219A2 may contribute to the development of disease is its role in the regulation of cell survival and apoptosis. MIR219A2 has been shown to play a role in the regulation of cell apoptosis, which is a natural mechanism that helps cells to remove themselves from the body when they are no longer needed. However, in some diseases, including neurodegenerative diseases, misregulated cell apoptosis can contribute to the development of progressive neurodegeneration. Therefore, targeting MIR219A2 may be a potential way to treat neurodegenerative diseases.
In addition to its potential drug target and biomarker properties, MIR219A2 also has interesting structural features that may make it a useful protein for research into various diseases. For example, MIR219A2 has a unique structure that includes a long terminal extension, also known as a C-terminal hypervariable region (HVR), which is often involved in protein-protein interactions and may be a potential binding site for small molecules or other proteins. Additionally, MIR219A2 has a propensity to form a binary complex with other proteins, which may have implications for its function in cellular signaling pathways.
Overall, MIR219A2 is a highly conserved non-coding RNA molecule that has the potential to be a drug target and biomarker for a variety of diseases. Its unique structure and various interactions with other proteins and signaling pathways suggest that MIR219A2 may be a valuable tool for the study of gene function and the development of new treatments for various diseases. Further research is needed to fully understand the role of MIR219A2 in disease and to develop effective treatments based on its unique properties.
Protein Name: MicroRNA 219a-2
The "MIR219A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR219A2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144
